# Study of YH004 (4-1BB Agonist Antibody) in Advanced Solid Tumors And Relapsed Or Refractory Non-Hodgkin Lymphoma

> **NCT05564806** · PHASE1 · UNKNOWN · sponsor: **Eucure (Beijing) Biopharma Co., Ltd** · enrollment: 38 (estimated)

## Conditions studied

- Advanced Solid Tumors
- Relapsed Or Refractory Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** YH004

## Key facts

- **NCT ID:** NCT05564806
- **Lead sponsor:** Eucure (Beijing) Biopharma Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-31
- **Primary completion:** 2025-10-24
- **Final completion:** 2026-02-07
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2023-09-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05564806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05564806, "Study of YH004 (4-1BB Agonist Antibody) in Advanced Solid Tumors And Relapsed Or Refractory Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05564806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*